Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $107.78 USD
Change Today +3.72 / 3.57%
Volume 741.5K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Thomas H. Tuschl Ph.D.

Member of Scientific Advisory Board, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 25 board members in 2 different organizations across 2 different industries.

See Board Relationships
----

Background*

Dr. Thomas H. Tuschl Ph.D. is an Associate Professor at Rockefeller University. Dr. Tuschl serves as a Member of the Scientific Advisory Board at Alnylam Pharmaceuticals Inc., and Regulus Therapeutics Inc.

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $107.78 USD +3.72

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$490.0K
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.